KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill & Intangibles (2022 - 2025)

Historic Goodwill & Intangibles for Halozyme Therapeutics (HALO) over the last 4 years, with Q3 2025 value amounting to $765.4 million.

  • Halozyme Therapeutics' Goodwill & Intangibles fell 849.44% to $765.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $765.4 million, marking a year-over-year decrease of 849.44%. This contributed to the annual value of $818.7 million for FY2024, which is 798.57% down from last year.
  • Halozyme Therapeutics' Goodwill & Intangibles amounted to $765.4 million in Q3 2025, which was down 849.44% from $783.1 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Goodwill & Intangibles peaked at $1.2 billion during Q2 2022, and registered a low of $765.4 million during Q3 2025.
  • Moreover, its 4-year median value for Goodwill & Intangibles was $880.8 million (2023), whereas its average is $905.7 million.
  • Within the past 5 years, the most significant YoY rise in Halozyme Therapeutics' Goodwill & Intangibles was 690.6% (2023), while the steepest drop was 2107.69% (2023).
  • Quarter analysis of 4 years shows Halozyme Therapeutics' Goodwill & Intangibles stood at $955.7 million in 2022, then decreased by 6.91% to $889.7 million in 2023, then fell by 7.99% to $818.7 million in 2024, then dropped by 6.51% to $765.4 million in 2025.
  • Its last three reported values are $765.4 million in Q3 2025, $783.1 million for Q2 2025, and $800.9 million during Q1 2025.